Research News 2

Research News

1 | 2 | 3 | 4 | 5 | 6 | 7

  • Peering Inside the Cell: A New Frontier in HIV Research

    A new method of mapping cellular proteins before and after viral infection—a prime example of “spatial proteomics”—could revolutionize strategies to combat HIV.


  • On the Same Page?

    Researchers, including amfAR grantee Dr. Rachel Rutishauser, seek to gain insights by harmonizing definitions and conclusions across HIV cure trials.


  • The “French Patient” May Be the Latest Person Cured of HIV

    Known as the “French Patient,” a woman who received a stem cell transplant with donor cells without intact CCR5 receptors is likely the latest HIV cure case.


  • Unmasking the Power of the Pediatric Immune System

    In a new study, researchers examine the impact of long-term antiretroviral therapy started during infancy on the HIV reservoir.


  • The Second Berlin Patient

    The second Berlin Patient HIV cure opens up new possibilities and amfAR researchers are working to make this strategy an accessible, affordable one.


  • Six Researchers, One Goal

    New amfAR grants totaling more than $2.5 million support strategies to cure HIV, from immunotherapy to latency-reversing and anti-cancer agents.


  • Inhibiting HIV by Host Cell Targeting Strategies


  • Beyond Stem Cell Transplantation?

    amfAR awards grants to researchers—Drs. Jonah Sacha, Elena Herrera-Carrillo, and Alexander Pasternak—who are testing innovative HIV cure strategies.


  • Predicting Changes in the HIV Reservoir

    Researchers zero in on a marker, sugar-protein Galectin-9, that might be able to target HIV persistence, the main barrier to a cure for people living with the virus.


  • A Possible New Avenue to a Cure

    A study of the Geneva patient, cured of HIV via a transplant with cells susceptible to infection, opens up new possibilities of eradicating the virus.


  • Lenacapavir Looks to Revolutionize HIV Prevention

    PURPOSE 2 study results show that a twice-yearly injectable HIV antiretroviral, lenacapavir, is highly effective as PrEP among MSM, transgender women and men who have sex with men, and others.


  • Researchers Identify a Novel Cell Protein that Can Control HIV Growth

    Researchers have discovered a cell protein that can restrict the late phases of HIV replication as well as that of pox viruses.


  • Next-Generation PrEP

    PURPOSE 1 trial results show that a twice-yearly injectable—lenacapavir for PrEP—is 100% effective at preventing HIV infection among cisgender women and girls.


  • Daily Updates from the 2024 International AIDS Conference

    Daily updates of sessions at AIDS 2024 cover research on curing HIV, HIV care, and AIDS policy from amfAR and others.


  • The Second Berlin Patient

    A seventh person, the second Berlin Patient, has been cured of HIV, providing new evidence that a stem cell transplant with a CCR5 gene mutation might not be the only path to a cure.


1 | 2 | 3 | 4 | 5 | 6 | 7